loading page

Nucleic Acid-based Small Molecules as Targeted Transcription Therapeutics for Immunoregulation
  • +7
  • Ganesh N. Pandian,
  • Dan Bai,
  • Reihane Ziadlou,
  • Thangavel Vaijayanthi,
  • Subramani Karthikeyan,
  • Shanmugavel Chinnathambi,
  • Anutthaman Parthasarathy,
  • Li Cai,
  • Marie-Charlotte Brüggen,
  • Hiroshi Sugiyama
Ganesh N. Pandian
Kyoto Daigaku

Corresponding Author:[email protected]

Author Profile
Dan Bai
Research and Development Institute of Northwestern Polytechnical University in Shenzhen
Author Profile
Reihane Ziadlou
UniversitatsSpital Zurich Dermatologische Klinik
Author Profile
Thangavel Vaijayanthi
Kyoto Daigaku
Author Profile
Subramani Karthikeyan
Vellore Institute of Technology - Chennai Campus
Author Profile
Shanmugavel Chinnathambi
Kyoto Daigaku
Author Profile
Anutthaman Parthasarathy
University of Bradford
Author Profile
Li Cai
Rutgers University Department of Biomedical Engineering
Author Profile
Marie-Charlotte Brüggen
UniversitatsSpital Zurich Dermatologische Klinik
Author Profile
Hiroshi Sugiyama
Kyoto Daigaku
Author Profile


Transcription therapy is an emerging approach that centers on identifying the factors associated with the malfunctioning gene transcription machinery that causes diseases and controlling them with designer agents. Until now, small molecule drugs targeting the epigenetic enzymes and critical signaling pathways have been the primary research focus in therapeutic gene modulation. However, nucleic acid-based small molecules have gained popularity in recent years as they could be pre-designed on demand to achieve operative control over the dynamic transcription machinery that governs how the immune system responds to diseases. Pyrrole-imidazole polyamides (PIPs) are well-established DNA-based small molecule gene regulators that overcome the limitations of their conventional counterparts owing to their sequence-targeted specificity, versatile regulatory efficiency and biocompatibility. Here, we emphasize the rational design of PIPs, their functional mechanism and their potential as targeted transcription therapeutics for diseases by regulating the immune response. Furthermore, we also discuss the challenges and foresight of this approach in personalized immunotherapy in precision medicine.
24 May 2023Submitted to Allergy
24 May 2023Submission Checks Completed
24 May 2023Assigned to Editor
24 May 2023Review(s) Completed, Editorial Evaluation Pending
29 May 2023Reviewer(s) Assigned
03 Jun 2023Editorial Decision: Revise Minor
01 Nov 20231st Revision Received
03 Nov 2023Review(s) Completed, Editorial Evaluation Pending
03 Nov 2023Submission Checks Completed
03 Nov 2023Assigned to Editor
05 Nov 2023Reviewer(s) Assigned
09 Nov 2023Editorial Decision: Accept